Skip to content
Open access

Rational Tuning of Intracellular Release Kinetics in PROTAC–Peptide Conjugates via Positional Modulation of Functional Peptide Domains

Aug 2026 · ACS Bio & Med Chem Au · 0 citations · 29 references

Abstract

Proteolysis-targeting chimeras (PROTACs) can induce degradation of otherwise challenging proteins, but their large size and unfavorable physicochemical properties often limit cellular delivery. We designed PROTAC–peptide conjugates containing a nona-arginine cell-penetrating peptide (R9), a redox-sensitive disulfide linker, and an aromatic-rich peptide sequence previously described as an endosomal escape domain (EED). The EED sequence was positioned at either the N- or C-terminus to examine how peptide-domain arrangement affects intracellular fluorescence, payload release, and BRD4 degradation. At 10 and 100 nM, the C-terminal variant MZ1-R9-EED produced a greater reduction in BRD4 abundance at 24 h than MZ1-R9 and MZ1-EED-R9, although the two-concentration comparison did not permit determination of DC50, Dmax, or hook effects. FAM-based flow cytometry yielded pH-sensitive cell-associated fluorescence signals that could not be interpreted as an absolute measure of total cellular uptake. Qualitative confocal microscopy showed punctate fluorescence with apparent LysoTracker overlap but did not provide quantitative evidence of endosomal escape. Under a defined cell-free reducing condition, MZ1-R9-EED underwent faster apparent disulfide cleavage, with a half-life of 0.21 h versus 0.36–0.47 h for the other conjugates, and yielded higher apparent intracellular free MZ1 levels under identical analytical conditions. Square-wave voltammetry revealed no substantial differences in reduction potential, whereas molecular dynamics simulations suggested a possible contribution of local steric accessibility. These findings associate peptide-domain positioning with cleavage kinetics, free-payload levels, and BRD4 reduction, identifying domain arrangement as a design variable for disulfide-linked PROTAC–peptide conjugates without establishing cleavage as the rate-limiting or causal mechanism.

Read PDF

Similar papers

Open access Sep 2026

Native Mass Spectrometry Reveals Distinct Effects of Linker Length and Targeting-Ligand Identity on PROTAC Ternary Complexes

Proteolysis-targeting chimeras (PROTACs) promote targeted protein degradation by inducing a transient ternary complex between a protein of interest and an E3 ubiquitin ligase. Despite the clinical promise of these event-driven therapeutics, defining the conformational landscape and interfacial organization of these com...

Evan N. Whitford, Joshua D. Gilbert, Marius M. Kostelic et al. · 0 citations
Open access Aug 2026

Structure-guided engineering of an aptamer–PROTAC for targeted degradation of vaccinia-related kinase 1

Vaccinia-related kinase 1 (VRK1) is an oncogenic serine/threonine kinase implicated in tumor progression, yet it remains an intractable target for catalytic degradation. Herein, we report the structure-guided design of a first aptamer–PROTAC chimera for potent and selective degradation of VRK1. Through structure-guided...

Yangfang Yun, Ya-Qing Gao, Yang Shi et al. · 1 citation
Open access Sep 2026

Mapping the Functional Landscape and Viral Diversity of 2A Peptides

A mammalian fluorescence resonance energy transfer (FRET) based high-throughput reporter system is developed to quantitatively measure 2A activity across large libraries of natural and engineered 2A peptides and provides mechanistic and evolutionary insights into how nascent peptide–ribosome exit tunnel interactions me...

Adesh Baral, Aditi Kothiala, K. X. Zhong et al. · 0 citations
Open access Sep 2026

The α-helix-facilitating amino acid sequence EAAAK dramatically increases the antiviral activity of SARS-CoV-2 fusion-inhibitory peptides via the endosome fusion pathway

It is demonstrated that the C-terminal EAAAK motif in IPB29—originally designed as a rigid linker connecting the peptide backbone to the lipid moiety—is critical for its antiviral activity and functions via the endosomal fusion pathway.

Zhi-Xin Yao, Yuan-Mei Zhu, Nian Liu et al. · 0 citations
Open access Sep 2026

Directed Oxidative Folding of Disulfide-Rich Peptides (DRPs) Using a Pseudoproline Unit: Ion Mobility-Mass Spectrometry (IM-MS) Reveals the Conformational Landscape of the DRP

Disulfide-rich peptides (DRPs) are attractive drug development scaffolds due to their exceptional stability and specificity. Regioselective disulfide bond formation is often achieved via orthogonal Cys protecting groups or strategic Pro placement. However, Cys protection strategies are labor-intensive and low-yielding,...

Declan T. Cook, Kish R. Adoni, Konstantinos Thalassinos et al. · 0 citations
Aug 2026

A Time-Resolved FRET Activity Assay to Distinguish Enzymatic Inhibition from PROTAC-Mediated Degradation of SARS-CoV-2 Mpro.

Proteolysis-targeting chimeras (PROTACs) are emerging as a promising strategy for antiviral drug development and are mechanistically distinct from classical small-molecule inhibitors. Many PROTAC designs targeting viral proteases, such as the SARS-CoV-2 main protease (Mpro), employ warheads derived from active-site inh...

C. Veeck, Luna C. Schmacke, Jasmin Jekkel et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.